Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas

Virchows Archiv

Volumn 466, Issue 4, 2015, Pages 415-422

  Coenegrachts, L ^a   Garcia Dios, D A ^a,b   Depreeuw, J ^a,b,c   Santacana, M ^d   Gatius, S ^d   Zikan, M ^e   Moerman, P ^f   Verbist, L ^a   Lambrechts, D ^b,c   Matias Guiu, Xavier ^d,g   Amant, Frédéric ^a,f  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^e CHARLES UNIVERSITY   (Czech Republic)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY OF LLEIDA   (Spain)

Author keywords

Clinical outcome; Endometrial cancer; Mixed endometrial carcinomas; Mutation analysis

Indexed keywords

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MICROSATELLITE INSTABILITY; MIXED ENDOMETRIOID AND SEROUS ENDOMETRIAL CARCINOMA; MUTATION RATE; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE K RAS; OVERALL SURVIVAL; PIK3CA GENE; PRIORITY JOURNAL; PTEN GENE; RECURRENCE FREE SURVIVAL; TP53 GENE; AGED; CYSTADENOCARCINOMA; DISEASE FREE SURVIVAL; ENDOMETRIUM TUMOR; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MIXED TUMOR; MORTALITY; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL;

AGED; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASMS, COMPLEX AND MIXED; PROPORTIONAL HAZARDS MODELS;

EID: 84930739011     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-015-1728-5     Document Type: Article

References (14)

1. Amant F, Moerman P, Neven P, Timmerman D, Van LE, Vergote I (2005) Endometrial cancer. Lancet 366:491–505
2. Yeramian A, Moreno-Bueno G, Dolcet X, Catasus L, Abal M, Colas E et al (2013) Endometrial carcinoma: molecular alterations involved in tumor development and progression. Oncogene 32:403–413
3. Quddus MR, Sung CJ, Zhang C, Lawrence WD (2010) Minor serous and clear cell components adversely affect prognosis in “mixed-type” endometrial carcinomas: a clinicopathologic study of 36 stage-I cases. Reprod Sci 17:673–678
4. Roelofsen T, van Ham MA, Wiersma van Tilburg JM, Zomer SF, Bol M, Massuger LF et al (2012) Pure compared with mixed serous endometrial carcinoma: two different entities? Obstet Gynecol 120:1371–1381
5. McConechy MK, Ding J, Cheang MC, Wiegand KC, Senz J, Tone AA et al (2012) Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol 228:20–30
6. Kurman RJ, Carcangiu ML, Herrington CS, Young RH (2014) WHO classification of tumors of the female reproductive organs. WHO classification of tumors. IARC press, Lyon
7. Garcia-Dios DA, Lambrechts D, Coenegrachts L, Vandenput I, Capoen A, Webb PM et al (2013) High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. Gynecol Oncol 128:327–334
8. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L (2000) The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88:814–824
9. Zhang L, Liu Y, Hao S, Woda BA, Lu D (2011) IMP2 expression distinguishes endometrioid from serous endometrial adenocarcinomas. Am J Surg Pathol 35:868–872
10. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D et al (2011) COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39:D945–D950
11. Catasus L, Gallardo A, Cuatrecasas M, Prat J (2009) Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol 22:522–529
12. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H et al (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497:67–73
13. Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS (2011) Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 8:261–271
14. Myers AP (2013) New strategies in endometrial cancer: targeting the 449 PI3K/mTOR pathway—the devil is in the details. Clin Cancer Res 450 19:5264–5274